Incyte Corporation announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has endorsed a new indication for Zynyz (retifanlimab), an innovative cancer therapy developed in partnership with MacroGenics. This approval expands the drug’s use to treat specific gastrointestinal tract (GIT) cancers, offering fresh options for patients in Europe.
Details of the Endorsement
The expert panel’s decision builds on prior approvals and highlights Zynyz’s potential in addressing unmet needs in oncology. Retifanlimab, an anti-PD-1 monoclonal antibody, targets tumors by enhancing the immune system’s response. Incyte markets the therapy jointly with MacroGenics, leveraging their combined expertise to advance cancer treatments.
Impact on Treatment Landscape
This new GIT indication could improve access to effective immunotherapies for patients with advanced cancers in the region. Clinical data supporting the endorsement demonstrated promising efficacy and safety profiles, paving the way for broader integration into European healthcare protocols. Incyte plans to roll out the updated labeling soon, pending final regulatory steps.
